Adapting behavioral activation for perinatal depression and anxiety in response to the COVID-19 pandemic and racial injusticeRandomized Controlled Trial Published on 2022-02-152022-10-05 Journal: Journal of affective disorders [Category] COVID19(2023년), SARS, 임상, [키워드] Activation activity Analysis Anxiety anxiety symptom behavioral activation behavioural calculated Canada Care conducted connection COVID-19 COVID-19 pandemic Depression depressive Ethnicity event examined explicit facilitate facilitator Frequency Government group groups identify implementation lack non-inferiority offer pandemic participant Perinatal Perinatal depression Perspective Population Psychological treatments psychotherapy race race. Racial random Randomized controlled trial receiving reported Stressor Support Symptom therapeutic alliance Treatment USA was used women [DOI] 10.1016/j.jad.2021.12.006 PMC 바로가기 [Article Type] Randomized Controlled Trial
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종Clinical Trial Published on 2022-02-052022-08-13 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술, [키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine [DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial
The use of personal protection equipment does not negatively affect paramedics’ attention and dexterity: a prospective triple-cross over randomized controlled non-inferiority trialRandomized Controlled Trial Published on 2022-01-102022-10-04 Journal: Scandinavian Journal of Trauma, Resuscitation and [Category] SARS, 임상, [키워드] Affect Attention Cardiopulmonary resuscitation component Concentration concern conditions COVID-19 COVID-19 pandemic equipment evaluate healthcare impair increase Intervention Mask Masks Neurocognition no difference non-inferiority non-inferiority margin non-inferiority trial pandemic participated Patient Personal protection equipment PPE previous study Primary outcome Randomized recommendation Result SARS-COV-2 infection sequence significantly Support team widespread [DOI] 10.1186/s13049-021-00990-3 PMC 바로가기 [Article Type] Randomized Controlled Trial
Impact of the SARS-CoV-2 (COVID19) pandemic on the morbidity and mortality of high risk patients undergoing surgery: a non-inferiority retrospective observational studyObservational Study Published on 2021-11-262022-10-04 Journal: BMC Anesthesiology [Category] MERS, SARS, 임상, [키워드] Admission Care Clavien-Dindo complications complex Complication COVID COVID-19 crisis COVID-19 pandemic COVID19 Critical care deaths Elective surgery Emergent surgery generate group high risk Impact indicate limitations morbidity and mortality Mortality non-inferiority occurred Operating room outcome pandemic Patient Pneumonia positive postoperative Respiratory failure Result retrospective Safe SARS-CoV-2 (COVID19) pandemic severity severity of illness shown supplementary material surgical tested the SARS-CoV-2 [DOI] 10.1186/s12871-021-01495-3 PMC 바로가기 [Article Type] Observational Study
Partial oral antibiotic treatment for bacterial brain abscess: an open-label randomized non-inferiority trial (ORAL)Randomized Controlled Trial Published on 2021-11-122022-10-04 Journal: Trials [Category] MERS, 임상, [키워드] 1:1 Admission age all-cause mortality Alpha Antibiotic therapy Antibiotic treatment Antibiotics assigned Bacterial blinded Brain Brain abscess caused Cerebral abscess cognitive complications composite endpoint conducted Controlled trial criteria Date Denmark effective Endpoint EudraCT favor Follow-up France Health hospital Immunocompromise include independent International intravenous intraventricular investigator-initiated Netherlands non-inferiority non-inferiority trial Open-label oral outcome parallel group Partial Patient patients Pregnancy primary endpoint Pseudomona Quality of life randomization Randomized Randomized controlled trial recommendation recruitment Registered rupture Sample size scale secondary severe adverse events standard treatment suggested Treatment Tuberculosis [DOI] 10.1186/s13063-021-05783-8 PMC 바로가기 [Article Type] Randomized Controlled Trial
Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities진행 중인 및 미래의 COVID-19 백신 임상 시험: 도전과 기회Review Published on 2021-11-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] SARS, 임상, [키워드] Affect benefit candidate Candidates commitment Community Council country COVID-19 vaccine COVID-19 vaccines double-blind Host immune response International organizations knowledge Medical Science Medical Sciences non-inferiority older population organization Phase 2 phase 3 trial placebo-controlled placebo-controlled trial proportion randomised Research SARS-CoV-2 vaccine Sponsor Trial trial participant trial participants vaccine candidate vaccine candidates Vaccines WHO [DOI] 10.1016/S1473-3099(21)00263-2 PMC 바로가기 [Article Type] Review
Withania somnifera as a safer option to hydroxychloroquine in the chemoprophylaxis of COVID-19: Results of interim analysisRandomized Controlled Trial Published on 2021-11-012022-10-05 Journal: Complementary therapies in medicine [Category] 신약개발, 임상, [키워드] 95 % CI Arm Ashwagandha Ayurveda baseline characteristics benefit carried chain Chemoprophylaxis clinical benefit COVID-19 Efficacy Efficacy and safety evaluate expected Final HCQ HCW Health care worker high risk Hydroxychloroquine Hydroxychloroquine. immunomodulator interim analysis Mental mental health Mild non-inferiority non-inferiority margin Open-label participant physical Prophylaxis Quantitative Randomized reaction reducing reported Result RT-PCR Stress study period Symptom [DOI] 10.1016/j.ctim.2021.102768 PMC 바로가기 [Article Type] Randomized Controlled Trial
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19Review Article Published on 2021-10-282022-10-04 Journal: NPJ Vaccines [Category] 변종, 비임상, 임상, [키워드] addition Biological sciences Biomarker Cellular immune response COVID-19 cross-protective determinants domain dose full-length humoral immune response Infectious diseases natural infection neutralizing antibody non-inferiority offer pandemic PROTECT Protein RBD S-protein Safe SARS-CoV-2 spike the RBD vaccination Vaccine vaccine immunogen Vaccines variants of concern viral variant [DOI] 10.1038/s41541-021-00393-6 PMC 바로가기 [Article Type] Review Article
Effectiveness of expiratory technique and induced sputum in obtaining good quality sputum from patients acutely hospitalized with suspected lower respiratory tract infection: a statistical analysis plan for a randomized controlled trialRandomized Controlled Trial Published on 2021-10-022022-10-04 Journal: Trials [Category] MERS, 임상, [키워드] adverse effect Analysis Antibiotics Clinical practice collected Culture Data analysis data-driven database dependent on Diagnosis expiratory Forced expiratory technique good quality Gram stain Hospitalized Hypothesis Induced sputum intention-to-treat intervention group knowledge Lower respiratory tract non-inferiority Patient Pneumonia Pragmatic protocol Randomized Randomized controlled trial recruitment reproducibility respiratory infection respiratory tract infection sputum Sputum sample statistical analyses statistical analysis Statistical analysis plan Study design submitted suction supplementary material tracheal Tracheal suction Treatment Trial usual care group [DOI] 10.1186/s13063-021-05639-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial아데노바이러스 벡터화 및 mRNA COVID-19 백신(Com-COV)을 사용한 이종 대 상동 프라임-부스트 일정의 안전성 및 면역원성: 단일 맹검, 무작위, 비열등성 시험Clinical Trial Published on 2021-09-042022-09-11 Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, 진단, [키워드] (ChAdOx1 nCoV-19 Administered age anti-Spike IgG approved assigned AstraZeneca baseline blood test blood tests BNT BNT162b2 boost ChAd ChAdOx1 ChAdOx1 nCoV-19 Cohort Comorbidity comparison Concentration COVID-19 COVID-19 disease COVID-19 vaccine COVID-19 vaccines criteria dose Efficacy eight eligible eligible participant Eligible participants ELISA enrolled evaluate facilitate female participant force geometric mean geometric mean concentration geometric mean ratio GMR greater groups Heterologous heterologous prime-boost heterologous schedule heterologous schedules homologous homologous schedule hospitalisation immune immune responses immunisation immunogenicity immunology inferiority ISRCTN laboratory confirmation limit majority mRNA mRNA vaccine non-inferiority non-inferiority trial occurred Older participant per-protocol population Pfizer-BioNTech primary analysis primary endpoint prime-boost interval prime-boost intervals randomised Randomly reactogenic reactogenicity receive receiving recipient recruited referred to regimen Registered reported Safety safety analyses Safety analysis SARS-CoV-2 anti-spike IgG SARS-COV-2 infection Serious Adverse Event seronegative serum single-blind subset Support Task Force the SARS-CoV-2 the vaccine These data Trial vaccination Vaccine Vaccines vectored vaccine was done [DOI] 10.1016/S0140-6736(21)01694-9 PMC 바로가기 [Article Type] Clinical Trial